Your session is about to expire
← Back to Search
Loncastuximab Tesirine + Rituximab for Diffuse Large B-Cell Lymphoma (LOTIS-9 Trial)
LOTIS-9 Trial Summary
This trial is testing a new drug to see if it is effective and safe in patients with a specific type of cancer who are either unfit or frail.
LOTIS-9 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLOTIS-9 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 & 3 trial • 86 Patients • NCT03002038LOTIS-9 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Cohort B : Loncastuximab Tesirine + Rituximab (Lonca-R)
- Group 2: Cohort A : Loncastuximab Tesirine + Rituximab (Lonca-R)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there any availability for patients to take part in the experiment?
"As per the records available on clinicaltrials.gov, this medical study is still open for patient enrolment. The original posting date of this trial was June 21st 2022 while its last update came in November 2nd 2022."
What circumstances is Rituximab frequently employed to treat?
"Rituximab is frequently prescribed for the treatment of lung malignancies, including small cell lung cancer. Additionally, it has proved to be a viable remedy for thyroiditis and polyangium."
What is the current capacity of participants in this experimentation?
"The sponsor, ADC Therapeutics S.A., is mandating the recruitment of 80 qualified patients to continue with the study. Participants will be sourced from Virginia Cancer Specialists in Gainesville and Texas Oncology - Medical City Dallas in Dallas respectively."
How widespread is the implementation of this research study in Canada?
"For this medical trial, Virginia Cancer Specialists, PC in Gainesville, Texas Oncology - Medical City Dallas in Dallas and Williamette Valley Cancer Institute and Research in Eugene are only three of the nine total sites offering participation."
Could you elucidate other experiments that have utilized Rituximab?
"Currently, there are 1,431 trials being conducted to evaluate the efficacy of rituximab. Of those investigations, 311 have advanced to Phase 3 clinicals in 51783 sites across the globe; however, most studies for Rituximab are concentrated in Bethesda Maryland."
Has Rituximab achieved regulatory authorization from the FDA?
"The safety of Rituximab is estimated to be a 2 due to the limited evidence that has been amassed in Phase 2 trials. While there are some data points supporting its security, none have yet verified efficacy."
Share this study with friends
Copy Link
Messenger